85 related articles for article (PubMed ID: 8569784)
1. ras oncoproteins in human plasma from lung cancer patients and healthy controls.
Anderson D; Hughes JA; Cebulska-Wasilewska A; Nizankowska E; Graca B
Mutat Res; 1996 Jan; 349(1):121-6. PubMed ID: 8569784
[TBL] [Abstract][Full Text] [Related]
2. Levels of ras oncoproteins in human plasma from 1,3-butadiene-exposed workers and controls.
Anderson D; Hughes JA; Brinkworth MH; Peltonen K; Sorsa M
Mutat Res; 1996 Jan; 349(1):115-20. PubMed ID: 8569783
[TBL] [Abstract][Full Text] [Related]
3. Ras p21 protein levels in human plasma from patients with chronic obstructive pulmonary disease (COPD) compared with lung cancer patients and healthy controls.
Anderson D; Hughes JA; Cebulska-Wasilewska A; Nizankowska E; Graca B
Mutat Res; 1998 Jul; 403(1-2):229-35. PubMed ID: 9726023
[TBL] [Abstract][Full Text] [Related]
4. Expression of ras (p21) protein in plasma from exposed workers and from patients with lung disease.
Anderson D
Int J Hyg Environ Health; 2001 Oct; 204(1):55-60. PubMed ID: 11725347
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting various biomarkers in untreated lung cancer patients and healthy donors.
Anderson D; Hughes JA; Nizankowska E; Graca B; Cebulska-Wasilewska A; Wierzewska A; Kasper E
Environ Mol Mutagen; 1997; 30(2):205-16. PubMed ID: 9329645
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic damage and ras p21 oncoprotein levels from patients with chronic obstructive pulmonary disease (COPD), untreated lung cancer and healthy controls.
Cebulska-Wasilewska A; Wierzewska A; Nizankowska E; Graca B; Hughes JA; Anderson D
Mutat Res; 1999 Dec; 431(1):123-31. PubMed ID: 10656491
[TBL] [Abstract][Full Text] [Related]
7. Examination of ras oncoproteins in human plasma from healthy controls and workers exposed to petroleum emissions, including benzene-related compounds.
Anderson D; Hughes JA; Brinkworth MH; Cebulska-Wasilewska A; Nizankowska E; Graca B; Veidebaum T; Peltonen K; Sorsa M
Mutat Res; 1999 Sep; 445(2):167-73. PubMed ID: 10575427
[TBL] [Abstract][Full Text] [Related]
8. Examination of ras (P21) proteins in plasma from workers exposed to benzene emissions from petrochemical plants and healthy controls.
Anderson D; Hughes JA; Veidebaum T; Peltonen K; Sorsa M
Mutat Res; 1997 Nov; 381(2):149-55. PubMed ID: 9434871
[TBL] [Abstract][Full Text] [Related]
9. [Determination of Iodine-125 labelled monoclonal ras oncoprotein in plasma from non-smoking female lung cancer patients and healthy controls.].
Zhu L; Cheng J; Li H; Zhong L; Qu Y
Zhongguo Fei Ai Za Zhi; 1998 Jul; 1(1):37-9. PubMed ID: 20863462
[TBL] [Abstract][Full Text] [Related]
10. Serum ras (p21) as a marker for occupationally derived lung cancer?
Schneider J; Presek P; Braun A; Löffler S; Woitowitz HJ
Clin Chem Lab Med; 2000 Apr; 38(4):301-5. PubMed ID: 10928648
[TBL] [Abstract][Full Text] [Related]
11. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
[TBL] [Abstract][Full Text] [Related]
12. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
[TBL] [Abstract][Full Text] [Related]
13. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
Olsen CC; Schefter TE; Chen H; Kane M; Leong S; McCarter MD; Chen Y; Mack P; Eckhardt SG; Stiegmann G; Raben D
Am J Clin Oncol; 2009 Apr; 32(2):115-21. PubMed ID: 19307945
[TBL] [Abstract][Full Text] [Related]
14. Serum antibodies to retinal antigens in lung cancer and sarcoidosis.
Jankowska R; Witkowska D; Porebska I; Kuropatwa M; Kurowska E; Gorczyca WA
Pathobiology; 2004; 71(6):323-8. PubMed ID: 15627843
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas.
Magrisso IJ; Richmond RE; Carter JH; Pross CB; Gilfillen RA; Carter HW
Lab Invest; 1993 Dec; 69(6):674-81. PubMed ID: 8264230
[TBL] [Abstract][Full Text] [Related]
17. [Studies on serum regulatory protein for cell growth in patients with lung cancer exposed to indoor coal-burning].
Li J; Li X; Quan X
Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Mar; 31(2):92-4. PubMed ID: 9812620
[TBL] [Abstract][Full Text] [Related]
18. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
[No Abstract] [Full Text] [Related]
19. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
20. Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.
Gebauer F; Gelis S; Zander H; Meyer KF; Wolters-Eisfeld G; Izbicki JR; Bockhorn M; Tachezy M
Oncotarget; 2016 Apr; 7(15):20945-52. PubMed ID: 26967391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
